NLRP3 and Other metabolic disease: FMT successfully inhibited the cardiac NLRP3 inflammasome and ultimately attenuated increased AF susceptibility and cardiac fibrosis, suggesting that FMT-targeted inhibition of the NLRP3 inflammasome is a new innovative therapeutic option for metabolic diseases and cardiovascular diseases [177, 178].